Shots:
- The P-III DARE-19 trial involves assessing the efficacy and safety of Farxiga vs PBO in addition to SoC therapy in 1,250 hospitalized patients with COVID-19 who are at high risk of developing serious complications
- The trial fails to meet its 1EP of prevention measures organ dysfunction, all-cause mortality, and recovery measuring a change in clinical status (from early recovery to death) @30days, safety and tolerability profile of Farxiga was consistent with the established safety profile of the therapy
- Farxiga (PO, qd) is an SGLT2 inhibitor, approved for HFrEF in adults with/out T2D. The results will be presented at ACC in May’2021
Click here to read full press release/ article | Ref: AstraZeneca | Image: AL Jazeera
The post AstraZeneca’s Farxiga (dapagliflozin) Fails to Meet its Primary Endpoint in P-III DARE-19 Trial for COVID 19 first appeared on PharmaShots.
